New shot could replace daily pills for prostate cancer patients

NCT ID NCT07005154

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 22 times

Summary

This study tests a new injectable drug, ASP5541, for men with advanced prostate cancer that has spread. The drug is a different form of the standard treatment abiraterone, given as a shot every 12 weeks instead of daily pills. The study will compare how well the injection works and its safety against the usual oral medication, with or without a steroid. About 218 men with metastatic hormone-sensitive or castration-resistant prostate cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Associated Urological Specialists
RECRUITING

Chicago Ridge, Illinois, 60415, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Clearview Cancer Institute
RECRUITING

Huntsville, Alabama, 35805, United States
H. Lee Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Harasanshin Hospital
RECRUITING

Fukuoka, Japan
Huai'an First People's Hospital
RECRUITING

Huaian, 211731, China
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, Japan
New Mexico Oncology Hematology Consultants
RECRUITING

Albuquerque, New Mexico, 87109, United States
Nippon Medical School Hospital
RECRUITING

Bunkyo-ku, Tokyo, Japan
Ochsner Health - Ochsner Medical Center - New Orleans
RECRUITING

New Orleans, Louisiana, 70121, United States
Osaka International Cancer Institute
RECRUITING

Osaka, Japan
PanOncology Trials
RECRUITING

San Juan, Puerto Rico
Renji Hospital Shanghai Jiaotong Univ School of Medicine
RECRUITING

Shanghai, 200127, China
Shizuoka Cancer Center
RECRUITING

Sunto-gun, Shizuoka, Japan
Site DE49001
RECRUITING

Heinsberg, Germany
Site DE49004
RECRUITING

Nürtingen, Baden-Wurttemberg, Germany
Site ES34006
RECRUITING

Barcelona, Catalonia, Spain
Site FR33004
RECRUITING

Strasbourg, France
Site GB44003
RECRUITING

London, United Kingdom
Site KR82002
RECRUITING

Seoul, South Korea
Site KR82003
RECRUITING

Seoul, South Korea
Site KR82004
RECRUITING

Seoul, South Korea
Site KR82007
RECRUITING

Seoul, South Korea
Site KR82008
RECRUITING

Gwangju, South Korea
Site TW88602
RECRUITING

Taipei, Taiwan
Site TW88603
RECRUITING

Kaohsiung City, Taiwan
Solaris Health - The Urology Group
RECRUITING

Cincinnati, Ohio, 45212, United States
Subei People's Hospital
RECRUITING

Yangzhou, Jiangsu, 225001, China
Tennessee Oncology Nashville
RECRUITING

Nashville, Tennessee, 37203, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Koto, Tokyo, Japan
The Second Hospital of Tianjin Medical University
RECRUITING

Tianjin, Tianjin Municipality, 300211, China
UW Health Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22908-07, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PROSTATE CANCER